低リスクの非浸潤性乳管癌(DCIS)における乳房温存手術単独の前向き評価 (ELISA)
臨床病理学的特徴と組み合わせた分子発現アッセイによって定義された、低リスクの乳管上皮内癌における乳房温存手術単独の前向き評価
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
調査の概要
状態
条件
詳細な説明
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.
At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.
Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre
-
Edmonton、Alberta、カナダ、T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Abbotsford British Columbia、British Columbia、カナダ、V2S 0C2
- BC Cancer - Abbotsford Centre
-
Prince George、British Columbia、カナダ、V2M 7E9
- BC Cancer - Centre for the North (Prince George)
-
Surrey、British Columbia、カナダ、V3V 1Z2
- BC Cancer - Fraser Valley Centre
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- BC Cancer - Vancouver Centre
-
Victoria、British Columbia、カナダ、V8R 6V5
- BC Cancer - Victoria
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 1V7
- QE II HSC - Nova Scotia Cancer Centre
-
Sydney、Nova Scotia、カナダ、B1P 1P3
- Cape Breton Cancer Centre
-
-
Ontario
-
Barrie、Ontario、カナダ、L4M 6M2
- Royal Victoria Regional Health Centre
-
Hamilton、Ontario、カナダ、L8V 5C2
- Juravinski Cancer Centre
-
London、Ontario、カナダ、N6A 4L6
- London Regional Cancer Program
-
Thunder Bay、Ontario、カナダ、P7B 6V4
- Regional Cancer Care, Thunder Bay Regional Health Sciences Centre
-
Toronto、Ontario、カナダ、M4N 3M5
- Sunnybrook Health Science Centre -Odette Cancer Centre
-
Toronto、Ontario、カナダ、M5G 2M9
- University Health Network - Princess Margaret Cancer Centre
-
Windsor、Ontario、カナダ、N8W 2X3
- Windsor Regional Cancer Centre
-
-
Quebec
-
Greenfield Park、Quebec、カナダ、J4V 2H1
- Hôpital Charles Le Moyne (CISSS de la Montérégie-Centre)
-
Montreal、Quebec、カナダ、H4A 3J1
- McGill University Health Centre
-
Montreal、Quebec、カナダ、H2L 4M1
- CHUM - Centre Hospitalier de L'Université de Montréal
-
Québec、Quebec、カナダ、G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec - Université Laval
-
Trois-Rivières、Quebec、カナダ、G8Z 3R9
- Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie- Centre-du-Québec (CIUSSS MCQ) - Trois-Rivières
-
-
Saskatchewan
-
Regina、Saskatchewan、カナダ、S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon、Saskatchewan、カナダ、S7N4H4
- Saskatoon Cancer Centre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.
Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment
説明
Inclusion Criteria:
-
Female patient > 45 years of age with DCIS without microinvasion.
-
Tumour size ≤ 2.5cm.
-
Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*
* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.
-
Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion Criteria:
- Multifocal DCIS.
- History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast.
- Synchronous or previous invasive or non-invasive breast cancer.
- Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers.
- ECOG performance status ≥3.
- Life expectancy <10 years.
- Geographic inaccessibility for follow-up.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Single Arm Cohort
Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Ipsilateral local recurrence (LR)
時間枠:5 Year
|
Defined as recurrent invasive or in situ cancer in the ipsilateral breast |
5 Year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Ipsilateral invasive local recurrence
時間枠:5 Year
|
defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast |
5 Year
|
|
Breast cancer recurrence-free interval (RFI)
時間枠:5 Year
|
defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer |
5 Year
|
|
Distant disease-free survival (DDFS)
時間枠:5 Year
|
defined as time from study registration to distant recurrence |
5 Year
|
|
Disease-free survival (DFS)
時間枠:5 Year
|
defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause |
5 Year
|
|
Overall survival (OS)
時間枠:5 Year
|
defined as time from registration to death of any cause |
5 Year
|
協力者と研究者
捜査官
- 主任研究者:Eileen Rakovitch, M.D.、Sunnybrook Research Institute, Sunnybrook Health Science
- 主任研究者:Tim Whelan, M.D、Juravinski Cancer Centre
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- OCOG-2021-ELISA
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。